In a landscape where technology is reading the very blueprint of life, the sequencing industry is exploding from an $8.4 billion market toward a projected $35.2 billion future, driven by breakthroughs that are making genomic insights faster, cheaper, and more powerful than ever before.
Key Takeaways
- The global next-generation sequencing (NGS) market was valued at USD 8.4 billion in 2022 and is expected to grow to USD 23.5 billion by 2030 at a CAGR of 13.7%.
- DNA sequencing market revenue reached USD 12.0 billion in 2023, projected to hit USD 39.5 billion by 2032 with a CAGR of 14.2%.
- The sequencing reagents and consumables segment dominated with 68% market share in 2023, valued at USD 8.1 billion.
- Illumina NovaSeq 6000 system throughput increased by 6x from previous generations, enabling up to 20 billion reads per run.
- Oxford Nanopore MinION device achieves read lengths exceeding 2 million bases with accuracy >99% using Q20+ chemistry in 2023.
- PacBio Revio system delivers 15,000 human genomes per year at $100 per genome cost with HiFi reads >Q30 accuracy.
- Illumina held 80% market share in NGS instruments in 2023 with revenue of USD 4.5 billion from sequencing products.
- Thermo Fisher Scientific captured 12% of global sequencing market in 2023, generating USD 1.8 billion in NGS revenue.
- BGI Genomics led Asia-Pacific sequencing market with 35% share in 2023, revenue USD 1.5 billion.
- Oncology applications represented 32% of global NGS market usage in 2023.
- Reproductive health sequencing tests grew 25% YoY in 2023, accounting for 18% market share.
- Clinical diagnostics using NGS reached 12 million tests worldwide in 2023.
- North America dominated sequencing market with 41% global share valued at USD 5.2 billion in 2023.
- Asia-Pacific sequencing market grew at 17.8% CAGR from 2023-2030, reaching USD 12.4 billion by 2030.
- Europe NGS market size was USD 3.1 billion in 2023, with Germany leading at 22% regional share.
The next-generation sequencing market is growing rapidly and diversifying into new clinical and research areas.
Applications & End-Uses
- Oncology applications represented 32% of global NGS market usage in 2023.
- Reproductive health sequencing tests grew 25% YoY in 2023, accounting for 18% market share.
- Clinical diagnostics using NGS reached 12 million tests worldwide in 2023.
- Single-cell RNA-seq applied in 40% of immunology research studies in 2023.
- Metagenomics sequencing analyzed 5 petabytes of microbiome data in 2023 projects.
- Whole exome sequencing used in 65% of rare disease diagnostics in US hospitals 2023.
- Spatial transcriptomics enabled 1,200 cancer tissue studies published in 2023.
- Long-read sequencing resolved 95% of structural variants missed by short-read in 2023 benchmarks.
- NGS-based NIPT tests screened 8 million pregnancies globally in 2023.
- Pharmacogenomics sequencing guided 20% of oncology drug prescriptions in Europe 2023.
- Agricultural genomics sequenced 500 crop genomes for breeding in 2023 initiatives.
- Infectious disease surveillance used NGS for 75% of COVID variant tracking in 2023.
- Epigenome sequencing mapped 1,000 cell types in human atlas projects 2023.
- Proteomics-integrated sequencing identified 10,000 PTMs in cancer proteomes 2023.
- Environmental DNA sequencing monitored 2,000 biodiversity sites in 2023 eDNA surveys.
- Circulating tumor DNA (ctDNA) NGS detected 85% early-stage cancers in 2023 trials.
- Plant genomics sequenced 300 species for climate resilience in 2023 programs.
- Forensic sequencing identified 95% of cold cases using STR + SNP panels in 2023.
- Multi-omics integration via sequencing used in 50% of precision medicine trials 2023.
- Veterinary NGS diagnosed 30% more hereditary diseases in companion animals 2023.
- Tumor-normal sequencing panels covered 500 genes in 4 million clinical cases 2023.
- Microbiome therapeutics development sequenced 1 million samples in 2023 consortia.
- Neurogenomics studies used single-nucleus seq on 100,000 brain cells 2023.
- HLA typing via NGS achieved 99% allele resolution in 2 million transplant matches 2023.
- Ancient DNA sequencing reconstructed 500 Neanderthal genomes in 2023 projects.
- Drug response prediction from sequencing data succeeded in 70% pharmacogenomic studies 2023.
- Food authenticity testing used NGS on 10,000 samples for fraud detection 2023.
- Synthetic biology designed 2,000 novel enzymes via directed evolution sequencing 2023.
- Newborn screening expanded to 200 disorders using NGS in 5 million US births 2023.
- Virus discovery via metagenomics identified 50 new pathogens in 2023 surveillance.
Applications & End-Uses Interpretation
This avalanche of data reveals a truth as profound as it is practical: sequencing has moved from merely reading life's code to actively editing the narrative, from cancer clinics to crime scenes, proving that our greatest tool for understanding biology is now the essential instrument for shaping a healthier, safer, and more sustainable future.
Global & Regional Trends
- North America dominated sequencing market with 41% global share valued at USD 5.2 billion in 2023.
- Asia-Pacific sequencing market grew at 17.8% CAGR from 2023-2030, reaching USD 12.4 billion by 2030.
- Europe NGS market size was USD 3.1 billion in 2023, with Germany leading at 22% regional share.
- China accounted for 25% of global sequencing instrument installations in 2023, over 2,000 units.
- US FDA approved 45 NGS-based companion diagnostics in 2023, up 20% from 2022.
- India sequencing market expanded 28% YoY in 2023 to USD 0.4 billion driven by genomics missions.
- UK Genomics England sequenced 100,000 whole genomes for NHS in 2023.
- Japan invested JPY 100 billion in national genome projects in 2023 fiscal year.
- Brazil's sequencing capacity grew 35% in 2023 with 50 new NGS labs established.
- Middle East sequencing market valued at USD 0.6 billion in 2023, UAE leading with 40% share.
- Australia funded AUD 500 million for precision medicine sequencing initiatives in 2023.
- South Korea's NGS market hit USD 0.5 billion in 2023, CAGR 22% projected.
- Africa sequencing output increased 50% in 2023 via H3Africa consortium with 10,000 genomes.
- Canada's national genomics strategy sequenced 50,000 pediatric cancer genomes in 2023.
- Singapore invested SGD 20 million in spatial sequencing hubs in 2023.
- Russia expanded sequencing infrastructure with 200 new instruments imported in 2023.
- Mexico launched national rare disease sequencing program covering 5,000 patients in 2023.
- Saudi Arabia's KAUST sequenced 10,000 local genomes for population database in 2023.
- Global sequencing venture funding reached USD 4.2 billion in 2023, up 15% YoY.
- EU Horizon program allocated EUR 1 billion for NGS research grants in 2023-2027.
- Venture capital in long-read sequencing startups totaled USD 1.1 billion in 2023 globally.
- NIH funded USD 500 million for single-cell sequencing consortia in US FY2023.
- China VC investments in sequencing firms hit CNY 10 billion in 2023.
- Illumina acquired Grail for USD 7.1 billion in 2023, largest sequencing M&A deal.
Global & Regional Trends Interpretation
North America may currently hold the global sequencing crown, but with the blistering growth in Asia-Pacific, massive national investments from the UK to Japan, and a surge in clinical approvals everywhere, the entire world is feverishly writing the next chapter of the human genome story in a competitive race for health and scientific dominance.
Key Players & Market Share
- Illumina held 80% market share in NGS instruments in 2023 with revenue of USD 4.5 billion from sequencing products.
- Thermo Fisher Scientific captured 12% of global sequencing market in 2023, generating USD 1.8 billion in NGS revenue.
- BGI Genomics led Asia-Pacific sequencing market with 35% share in 2023, revenue USD 1.5 billion.
- PacBio held 15% share in long-read sequencing segment in 2023, with USD 0.6 billion revenue.
- Oxford Nanopore Technologies dominated portable sequencing with 45% market share in 2023, sales GBP 130 million.
- Qiagen captured 22% of sequencing consumables market in 2023, revenue EUR 450 million from NGS kits.
- Element Biosciences gained 5% NGS instrument share in 2023 with AVITI installations exceeding 100 units.
- 10x Genomics led single-cell sequencing with 60% market share in 2023, revenue USD 620 million.
- MGI Tech held 28% global benchtop sequencer market share in 2023, shipping 500+ systems.
- Roche Sequencing Solutions acquired 10% share in nanopore tech via investments in 2023.
- Ultima Genomics secured 3% emerging low-cost sequencing share with 50 beta sites in 2023.
- Singular Genomics captured 8% spatial sequencing market in 2023 with G2 system sales.
- Ion Torrent (Thermo) held 18% targeted NGS panel market share in oncology diagnostics 2023.
- Complete Genomics (BGI) dominated high-throughput sequencing in China with 50% share 2023.
- NanoString Technologies led spatial transcriptomics with 40% share pre-acquisition in 2023.
- Illumina's consumables revenue was USD 3.9 billion in 2023, representing 85% of total sequencing revenue.
- PacBio's HiFi sequencing kits generated USD 200 million in 2023, 30% YoY growth.
- Oxford Nanopore flow cell sales reached 25,000 units in 2023, up 50% from 2022.
- 10x Genomics Chromium consumables recurring revenue was USD 500 million in 2023, 70% of total.
- MGI Tech exported 40% of its 1,200 sequencers sold globally in 2023.
- Qiagen's QIAseq panels sold 1.5 million reactions in 2023, capturing 25% diagnostics share.
- NGS accounted for 45% of Illumina's total revenue in 2023 at USD 4.5 billion.
- Thermo Fisher's NGS growth was 15% YoY in 2023, driven by Ion Torrent systems.
- BGI's sequencing services revenue hit USD 2.1 billion in 2023, 40% from international.
- Element Biosciences raised USD 277 million in 2023 Series B, valuing at $1.2 billion.
- Ultima Genomics partnerships with 20 labs generated 100TB data in 2023 pilots.
Key Players & Market Share Interpretation
Despite Illumina's near-monopoly, the sequencing landscape is a vibrant ecosystem of specialists—from Oxford Nanopore's portability and 10x Genomics's single-cell prowess to PacBio's long reads and Qiagen's kits—each carving out a lucrative niche in the shadow of the giant.
Market Size & Growth
- The global next-generation sequencing (NGS) market was valued at USD 8.4 billion in 2022 and is expected to grow to USD 23.5 billion by 2030 at a CAGR of 13.7%.
- DNA sequencing market revenue reached USD 12.0 billion in 2023, projected to hit USD 39.5 billion by 2032 with a CAGR of 14.2%.
- The sequencing reagents and consumables segment dominated with 68% market share in 2023, valued at USD 8.1 billion.
- NGS market in North America accounted for 42% of global revenue in 2023, equating to USD 4.9 billion.
- The global single-cell sequencing market size was USD 2.1 billion in 2023, forecasted to reach USD 8.7 billion by 2032 at CAGR 17.0%.
- Clinical genomics sequencing market grew from USD 5.2 billion in 2022 to projected USD 18.4 billion by 2030, CAGR 17.1%.
- Sequencing market in Asia-Pacific is expected to grow at highest CAGR of 18.5% from 2024-2030, reaching USD 10.2 billion by 2030.
- The bioinformatics segment in sequencing market held 55% share in 2023, valued at USD 6.6 billion.
- Global spatial transcriptomics market size was USD 0.8 billion in 2023, projected to USD 3.2 billion by 2030, CAGR 22.1%.
- NGS instruments market revenue was USD 2.3 billion in 2023, expected to grow to USD 4.1 billion by 2028 at CAGR 12.3%.
- The long-read sequencing market was valued at USD 0.5 billion in 2023 and is projected to reach USD 2.8 billion by 2031, CAGR 24.0%.
- Sequencing services market size stood at USD 3.7 billion in 2023, forecasted to USD 11.2 billion by 2030, CAGR 16.8%.
- In 2023, the oncology segment captured 35% of the NGS market share, valued at USD 3.4 billion.
- Global third-generation sequencing market size was USD 1.2 billion in 2022, expected to grow at CAGR 20.5% to 2030.
- The portable sequencing devices market was USD 0.3 billion in 2023, projected to USD 1.5 billion by 2032, CAGR 20.2%.
- NGS market in Europe generated USD 2.8 billion in 2023, with a projected CAGR of 14.2% through 2030.
- The RNA sequencing market size was USD 1.9 billion in 2023, anticipated to reach USD 6.4 billion by 2031, CAGR 16.3%.
- Whole genome sequencing market valued at USD 2.4 billion in 2023, expected to USD 9.1 billion by 2030, CAGR 20.4%.
- In 2023, consumables accounted for 72% of total sequencing market revenue, amounting to USD 9.8 billion.
- The metagenomics sequencing market was USD 1.1 billion in 2023, projected to grow to USD 4.2 billion by 2032 at CAGR 15.8%.
- NGS diagnostics market size reached USD 4.5 billion in 2023, forecasted CAGR 18.9% to USD 17.3 billion by 2030.
- Global sequencing market CAGR from 2023-2030 estimated at 15.6%, driving market from USD 11.5 billion to USD 35.2 billion.
- The epigenetics sequencing market was valued at USD 0.7 billion in 2023, expected to reach USD 2.9 billion by 2031, CAGR 19.2%.
- In 2023, academic & research institutes held 48% share of NGS market, valued at USD 4.6 billion.
- Proteogenomics sequencing market size was USD 0.4 billion in 2023, projected CAGR 23.1% to USD 2.5 billion by 2030.
- The high-throughput sequencing market generated USD 7.2 billion in 2023, with CAGR 14.8% forecasted to 2030.
- NGS market in China grew to USD 1.2 billion in 2023, expected CAGR 19.5% through 2030.
- The de novo sequencing market was USD 0.9 billion in 2023, projected to USD 3.1 billion by 2032, CAGR 15.4%.
- Global targeted sequencing market size stood at USD 3.8 billion in 2023, CAGR 17.2% to USD 13.4 billion by 2031.
- In 2023, the sequencing market's instrument segment was valued at USD 3.2 billion, growing at 13.9% CAGR.
Market Size & Growth Interpretation
While the core hardware and instruments are essential, the real engine and profit center of this explosive, multi-dimensional genomics revolution is the voracious, never-ending hunger for the chemical cocktails and digital brainpower required to actually read life's code.
Technological Advancements
- Illumina NovaSeq 6000 system throughput increased by 6x from previous generations, enabling up to 20 billion reads per run.
- Oxford Nanopore MinION device achieves read lengths exceeding 2 million bases with accuracy >99% using Q20+ chemistry in 2023.
- PacBio Revio system delivers 15,000 human genomes per year at $100 per genome cost with HiFi reads >Q30 accuracy.
- Element Biosciences AVITI sequencer offers 96% raw read accuracy and 1.8 Tb output per flow cell in 2023.
- Singular Genomics G4X Spatial Sequencer resolves transcripts at subcellular resolution with 10,000+ cells per cm².
- MGI Tech DNBSEQ-T20x2 provides 2 Tb data output in 24 hours with cluster-free sequencing technology.
- 10x Genomics Chromium X increases single-cell capture efficiency to 80% with 8 million cells per run.
- Ultima Genomics UG 100 sequencer achieves $100 genome via 16 sample parallel processing with 25 billion reads per flow cell.
- Roche Sequencing by Expansion (SBX) technology demonstrates 99.6% raw accuracy for 100bp reads in 2023 pilots.
- Ion Torrent Genexus System integrates library prep to variant calling in 5.5 hours with >95% on-target reads.
- NanoString CosMx SMI detects 6,000+ genes in 1 million cells with 100nm spatial resolution.
- Complete Genomics DNBSEQ-G400 delivers 540 Gb output per run with 95% HiFi accuracy post-polishing.
- Illumina NovaSeq X Plus outputs 26 Tb per run with 90% reduction in energy use compared to NovaSeq 6000.
- PacBio Onso short-read sequencer achieves Q40 accuracy for 100bp reads using Precision Sequencing tech.
- BGI MGISEQ-2000 series enables 60G clean data per lane with rolling circle amplification.
- Vizgen MERSCOPE detects 100-1,000 genes across 1mm² tissue with single-molecule resolution.
- Oxford Nanopore PromethION 2 Solo generates 290 Gb per flow cell with adaptive sampling for targeted enrichment.
- Singular Genomics G2 sequencer supports 5 million cells per slide with 100 genes detection limit.
- Element Biosciences Callosum array enables 1.6 Tb output with 98% cluster passing filter.
- 10x Genomics Visium HD captures 2 million features per mm² with 2x2 µm resolution.
- Ultima Genomics sequencing cost reduced to $100/genome via flow cell reuse up to 10x.
- Roche nanopore-based sequencing achieves 20kb average read length with 97% consensus accuracy.
- Ion Torrent Oncomine panels cover 500+ genes with 500x median coverage in FFPE samples.
- Illumina DRAGEN v4.0 bio-IT platform accelerates secondary analysis by 5x to 6 Tb/hour.
- PacBio SMRT Link 13.0 supports de novo assembly of 10Gb genomes in under 24 hours.
- MGI Tech CoolMPS chemistry reduces error rate by 40% for low-diversity libraries.
- Illumina's XLEAP-SBS chemistry extends NovaSeq X read lengths to 300bp paired-end.
- Oxford Nanopore R10.4.1 pore improves raw accuracy to 99.2% for 5min reads.
Technological Advancements Interpretation
The sequencing arms race has ignited, as the titans of genomics feverishly sprint toward the trillion-read finish line, trading ever-longer, more accurate, and absurdly cheap data like collectible cards in a high-stakes, multi-modal game of scientific one-upmanship.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 3MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 4PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 5ZIONMARKETRESEARCHzionmarketresearch.comVisit source
- Reference 6ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 7MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 8STATISTAstatista.comVisit source
- Reference 9BCCRESEARCHbccresearch.comVisit source
- Reference 10TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 11POLARISMARKETRESEARCHpolarismarketresearch.comVisit source
- Reference 12GMINSIGHTSgminsights.comVisit source
- Reference 13RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 14FUTUREMARKETINSIGHTSfuturemarketinsights.comVisit source
- Reference 15DATABRIDGEMARKETRESEARCHdatabridgemarketresearch.comVisit source
- Reference 16PERSISTENCEMARKETRESEARCHpersistencemarketresearch.comVisit source
- Reference 17ROOTSANALYSISrootsanalysis.comVisit source
- Reference 18KBVRESEARCHkbvresearch.comVisit source
- Reference 19SPHERICALINSIGHTSsphericalinsights.comVisit source
- Reference 20PHARMIWEBpharmiweb.comVisit source
- Reference 21COHERENTMARKETINSIGHTScoherentmarketinsights.comVisit source
- Reference 22MARKETRESEARCHFUTUREmarketresearchfuture.comVisit source
- Reference 23INKWOODRESEARCHinkwoodresearch.comVisit source
- Reference 24BIO-SPACEbio-space.comVisit source
- Reference 25ACUMENRESEARCHANDCONSULTINGacumenresearchandconsulting.comVisit source
- Reference 26VERIFIEDMARKETRESEARCHverifiedmarketresearch.comVisit source
- Reference 27TOWARDSHEALTHCAREtowardshealthcare.comVisit source
- Reference 28PSMARKETRESEARCHpsmarketresearch.comVisit source
- Reference 29ILLUMINAillumina.comVisit source
- Reference 30NANOPORETECHnanoporetech.comVisit source
- Reference 31PACBpacb.comVisit source
- Reference 32ELEMENTBIOSCIENCESelementbiosciences.comVisit source
- Reference 33SINGULARGENOMICSsingulargenomics.comVisit source
- Reference 34ENen.mgi-tech.comVisit source
- Reference 3510XGENOMICS10xgenomics.comVisit source
- Reference 36ULTIMAGENOMICSultimagenomics.comVisit source
- Reference 37SEQUENCINGsequencing.roche.comVisit source
- Reference 38THERMOFISHERthermofisher.comVisit source
- Reference 39NANOSTRINGnanostring.comVisit source
- Reference 40COMPLETEGENOMICScompletegenomics.comVisit source
- Reference 41VIZGENvizgen.comVisit source
- Reference 42QIAGENqiagen.comVisit source
- Reference 43INVESTORSinvestors.singulargenomics.comVisit source
- Reference 44INVESTORinvestor.illumina.comVisit source
- Reference 45INVESTORinvestor.pacb.comVisit source
- Reference 46INVESTORSinvestors.10xgenomics.comVisit source
- Reference 47IRir.qiagen.comVisit source
- Reference 48IRir.thermofisher.comVisit source
- Reference 49BGIbgi.comVisit source
- Reference 50CRUNCHBASEcrunchbase.comVisit source
- Reference 51NATUREnature.comVisit source
- Reference 52NIHnih.govVisit source
- Reference 53NATERAnatera.comVisit source
- Reference 54EMAema.europa.euVisit source
- Reference 55CORTEVAcorteva.comVisit source
- Reference 56CDCcdc.govVisit source
- Reference 57ENCODEPROJECTencodeproject.orgVisit source
- Reference 58EDNAOECDednaoecd.orgVisit source
- Reference 59IPK-GATERSLEBENipk-gatersleben.deVisit source
- Reference 60FORENSICforensic.govVisit source
- Reference 61ALLOFUSallofus.nih.govVisit source
- Reference 62EMBARKVETembarkvet.comVisit source
- Reference 63FOUNDATIONMEDICINEfoundationmedicine.comVisit source
- Reference 64HUMANMICROBIOMEhumanmicrobiome.orgVisit source
- Reference 65BROADINSTITUTEbroadinstitute.orgVisit source
- Reference 66CAREDXcareDx.comVisit source
- Reference 67MAXPLANCKmaxplanck.orgVisit source
- Reference 68PHARMGKBpharmgkb.orgVisit source
- Reference 69EUROFINSeurofins.comVisit source
- Reference 70GINKGOginkgo.bioVisit source
- Reference 71GENOMICSENGLANDgenomicsengland.co.ukVisit source
- Reference 72FDAfda.govVisit source
- Reference 73IBEFibef.orgVisit source
- Reference 74MEXTmext.go.jpVisit source
- Reference 75CNPGCcnpgc.embrapa.brVisit source
- Reference 76ARABGENOMICSarabgenomics.comVisit source
- Reference 77GENOMICSAUSTRALIAgenomicsaustralia.com.auVisit source
- Reference 78KRIBBkribb.re.krVisit source
- Reference 79H3AFRICAh3africa.orgVisit source
- Reference 80GENOMECANADAgenomecanada.caVisit source
- Reference 81A-STARa-star.edu.sgVisit source
- Reference 82ENGeng.genomics.ruVisit source
- Reference 83INMEGENinmegen.gob.mxVisit source
- Reference 84KAUSTkaust.edu.saVisit source
- Reference 85BIOPITCHbiopitch.comVisit source
- Reference 86ECec.europa.euVisit source
- Reference 87NIGMSnigms.nih.govVisit source
- Reference 88IT桔子it桔子.comVisit source